Free Trial
→ Nobody Understands Why Trump Is Invading Iran (here’s the answer) (From Banyan Hill Publishing) (Ad)tc pixel Free SBRA Stock Alerts

Sabra Healthcare REIT (SBRA) Financials

Sabra Healthcare REIT logo
$20.38 -0.08 (-0.39%)
Closing price 04:00 PM Eastern
Extended Trading
$20.38 0.00 (-0.02%)
As of 05:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Sabra Healthcare REIT

Annual Income Statements for Sabra Healthcare REIT

This table shows Sabra Healthcare REIT's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 69 60 148 269 69 138 -113 -78 14 127 156
Consolidated Net Income / (Loss)		 79 70 158 279 69 138 -113 -78 14 127 156
Net Income / (Loss) Continuing Operations		 79 70 158 279 69 138 -113 20 17 127 152
Total Pre-Tax Income 		80 71 159 288 79 156 81 22 19 128 153
Total Revenue		 241 265 320 625 647 586 437 518 649 706 788
Net Interest Income / (Expense)		 0.00 0.00 -88 0.00 0.00 0.00 -99 -105 0.00 0.00 0.00
Total Interest Income		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Interest Expense		 0.00 0.00 88 0.00 0.00 0.00 99 105 0.00 0.00 0.00
Total Non-Interest Income		 241 265 408 625 647 586 535 623 649 706 788
Service Charges on Deposit Accounts		 3.51 7.79 26 - - 156 156 187 236 285 357
Other Service Charges		 28 38 18 91 212 14 18 36 38 40 58
Net Realized & Unrealized Capital Gains on Investments		 -0.16 -6.68 -0.55 -2.92 -16 -14 -35 -0.41 -1.54 0.00 -1.15
Other Non-Interest Income		 210 225 364 537 452 431 397 401 376 381 374
Provision for Credit Losses		 - - - - - - 3.94 0.14 0.19 -0.57 -1.05
Total Non-Interest Expense		 161 193 213 466 571 447 556 484 553 581 632
Other Operating Expenses		 16 18 32 37 31 33 35 40 47 50 54
Depreciation Expense		 63 68 114 191 182 177 179 188 183 170 187
Impairment Charge		 0.00 30 1.33 1.41 122 4.00 9.50 94 14 18 7.32
Other Special Charges		 75 76 35 236 236 234 333 163 308 342 384
Nonoperating Income / (Expense), net		 - - 52 128 2.30 - 12 -12 -77 2.10 -3.52
Income Tax Expense		 0.75 1.05 0.65 3.01 3.40 0.71 1.85 1.24 2.00 1.01 1.84
Other Adjustments to Consolidated Net Income / (Loss)		 - - - - - - - -98 -2.90 -0.40 3.93
Net Income / (Loss) Attributable to Noncontrolling Interest		 -0.03 -0.07 -0.02 0.03 0.02 - - - 0.00 0.00 -0.10
Basic Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.67 ($0.52) ($0.34) $0.06 $0.54 $0.64
Weighted Average Basic Shares Outstanding		 62.24M 65.28M 105.62M 178.31M 187.17M 206.22M 219.07M 230.95M 231.20M 233.50M 241.31M
Diluted Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.67 ($0.52) ($0.34) $0.06 $0.54 $0.64
Weighted Average Diluted Shares Outstanding		 62.46M 65.52M 105.84M 178.72M 188.13M 207.25M 219.07M 230.95M 232.79M 236.05M 244.50M
Weighted Average Basic & Diluted Shares Outstanding		 62.30M 65.30M 105.80M 178.40M 205.27M 210.72M 230.90M 231.16M 231.48M 237.91M 252.15M
Cash Dividends to Common per Share		 $1.60 $1.67 $1.73 $1.80 $1.80 $1.35 $1.20 $1.20 $1.20 $1.20 $1.20

Quarterly Income Statements for Sabra Healthcare REIT

This table shows Sabra Healthcare REIT's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -15 17 26 24 30 47 40 66 23 27 41
Consolidated Net Income / (Loss)		 -15 17 26 24 30 47 40 66 23 27 41
Net Income / (Loss) Continuing Operations		 -14 19 27 24 30 47 40 65 21 25 39
Total Pre-Tax Income 		-14 18 27 24 29 47 40 65 22 26 39
Total Revenue		 136 135 139 147 149 156 156 176 159 296 193
Net Interest Income / (Expense)		 -28 -28 -28 -29 -29 -28 -27 -28 -29 84 -28
Total Interest Income		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Interest Expense		 28 28 28 29 29 28 27 28 29 -84 28
Long-Term Debt Interest Expense		 28 28 28 29 29 28 27 28 29 - 28
Total Non-Interest Income		 164 163 168 176 178 184 184 204 188 212 222
Service Charges on Deposit Accounts		 60 61 66 68 74 77 77 79 92 108 117
Other Service Charges		 11 9.13 9.70 9.18 9.70 11 10 25 12 11 9.96
Other Non-Interest Income		 93 93 92 99 95 96 96 100 85 93 95
Provision for Credit Losses		 0.33 -0.36 -0.14 -0.16 -0.15 -0.13 -0.17 -0.23 -0.24 -0.41 -0.21
Total Non-Interest Expense		 103 116 112 125 114 115 116 121 133 261 154
Other Operating Expenses		 11 17 12 13 12 13 13 13 13 16 15
Depreciation Expense		 43 43 43 42 43 42 43 44 49 51 53
Impairment Charge		 0.00 7.27 3.14 15 0.00 - 0.00 4.10 2.57 0.65 0.44
Other Special Charges		 49 49 54 55 59 59 60 61 70 193 86
Income Tax Expense		 0.46 0.49 0.45 0.44 -0.27 0.38 0.41 0.50 0.44 0.49 0.53
Other Adjustments to Consolidated Net Income / (Loss)		 -0.65 - -0.60 0.08 0.21 - 0.22 0.83 1.23 1.65 1.91
Net Income / (Loss) Attributable to Noncontrolling Interest		 - - - - 0.00 - 0.00 - -0.02 - -0.07
Basic Earnings per Share		 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.28 $0.09 $0.10 $0.16
Weighted Average Basic Shares Outstanding		 231.22M 231.20M 231.45M 231.62M 234.29M 233.50M 237.89M 237.98M 239.90M 241.31M 252.14M
Diluted Earnings per Share		 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.27 $0.09 $0.11 $0.16
Weighted Average Diluted Shares Outstanding		 231.22M 232.79M 233.37M 233.75M 237.04M 236.05M 240.30M 240.93M 243.56M 244.50M 255.97M
Weighted Average Basic & Diluted Shares Outstanding		 231.22M 231.48M 231.50M 234.26M 236.59M 237.91M 237.94M 239.79M 249.35M 252.15M 252.19M
Cash Dividends to Common per Share		 $0.30 - $0.30 $0.30 $0.30 - $0.30 $0.30 $0.30 - $0.30

Annual Cash Flow Statements for Sabra Healthcare REIT

This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -54 17 552 -527 -11 16 50 -62 -6.60 20 11
Net Cash From Operating Activities		 121 176 136 361 372 355 356 316 301 311 349
Net Cash From Continuing Operating Activities		 121 176 136 361 372 355 356 316 301 311 349
Net Income / (Loss) Continuing Operations		 79 70 158 279 69 138 -113 -78 14 127 156
Consolidated Net Income / (Loss)		 79 70 158 279 69 138 -113 -78 14 127 156
Provision For Loan Losses		 13 5.54 17 39 1.24 1.86 3.94 0.14 0.19 -0.57 -1.05
Depreciation Expense		 63 68 114 191 182 177 179 188 183 170 187
Amortization Expense		 5.28 5.68 7.78 10 10 8.42 8.37 11 12 10 7.97
Non-Cash Adjustments to Reconcile Net Income		 -20 21 -73 -141 134 32 256 214 94 27 9.04
Changes in Operating Assets and Liabilities, net		 -20 4.97 -88 -18 -24 -2.74 23 -20 -2.73 -23 -9.85
Net Cash From Investing Activities		 -489 142 -183 -258 263 -136 -336 -216 103 -109 -378
Net Cash From Continuing Investing Activities		 -489 142 -183 -258 263 -136 -336 -216 103 -109 -378
Purchase of Property, Leasehold Improvements and Equipment		 -3.69 -1.00 -6.95 -28 -25 -47 -43 -54 -85 -55 -42
Purchase of Investment Securities		 -524 -171 -440 -672 -64 -111 -397 -267 -106 -162 -461
Sale and/or Maturity of Investments		 33 314 183 434 347 22 104 101 289 102 122
Other Investing Activities, net		 - - 3.76 6.87 5.08 0.00 0.00 4.60 5.46 5.94 2.53
Net Cash From Financing Activities		 314 -301 599 -629 -646 -202 30 -162 -410 -182 41
Net Cash From Continuing Financing Activities		 314 -300 599 -629 -646 -202 30 -162 -410 -182 41
Issuance of Debt		 289 69 434 0.00 639 0.00 792 204 -92 15 610
Issuance of Common Equity		 139 - - - 549 - 309 -4.81 -2.68 86 228
Repayment of Debt		 -3.13 -244 -4.15 -159 -1,483 -3.07 -798 -81 -1.98 -2.03 -505
Payment of Dividends		 -110 -119 -182 -325 -335 -278 -263 -277 -277 -280 -289
Other Financing Activities, Net		 -1.27 -5.94 351 -0.49 -16 -0.83 -9.32 -2.52 -36 -0.09 -2.36
Cash Interest Paid		 54 59 70 138 124 93 85 98 102 105 111
Cash Income Taxes Paid		 0.66 0.85 0.71 1.80 3.91 2.44 1.84 1.66 1.67 1.39 1.50

Quarterly Cash Flow Statements for Sabra Healthcare REIT

This table details how cash moves in and out of Sabra Healthcare REIT's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 6.75 7.60 19 -24 27 -2.44 -37 73 106 -130 45
Net Cash From Operating Activities		 83 79 53 80 98 80 80 81 100 87 98
Net Cash From Continuing Operating Activities		 83 79 53 80 98 80 80 81 100 87 98
Net Income / (Loss) Continuing Operations		 -15 17 26 24 30 47 40 66 23 27 41
Consolidated Net Income / (Loss)		 -15 17 26 24 30 47 40 66 23 27 41
Provision For Loan Losses		 0.33 -0.36 -0.14 -0.16 -0.15 -0.13 -0.17 -0.23 -0.24 -0.41 -0.21
Depreciation Expense		 43 43 43 42 43 42 43 44 49 51 53
Amortization Expense		 3.09 3.09 3.07 3.07 2.61 1.73 1.73 1.73 2.15 2.36 2.37
Non-Cash Adjustments to Reconcile Net Income		 45 11 8.33 14 8.79 -3.89 2.44 -23 19 11 1.68
Changes in Operating Assets and Liabilities, net		 6.65 4.91 -28 -2.05 14 -6.75 -7.53 -6.23 8.17 -4.27 0.58
Net Cash From Investing Activities		 60 -62 -13 -57 -57 19 -16 -45 -200 -117 -105
Net Cash From Continuing Investing Activities		 60 -62 -13 -57 -57 19 -16 -45 -200 -117 -105
Purchase of Property, Leasehold Improvements and Equipment		 -26 -21 -13 -12 -14 -16 -7.78 -5.79 -11 -17 -12
Purchase of Investment Securities		 -0.90 -41 -1.30 -56 -80 -19 -11 -55 -241 -155 -96
Sale and/or Maturity of Investments		 86 -0.20 0.39 6.96 36 59 1.13 15 54 52 2.05
Other Investing Activities, net		 0.70 0.63 0.62 4.11 0.60 -5.32 0.81 0.56 -1.87 3.03 0.83
Net Cash From Financing Activities		 -136 -9.36 -20 -46 -14 -101 -101 37 206 -101 52
Net Cash From Continuing Financing Activities		 -136 -9.36 -20 -46 -14 -101 -101 37 206 -101 52
Issuance of Debt		 -66 61 52 -15 22 -59 -24 79 620 -65 138
Issuance of Common Equity		 -0.04 -0.49 -2.61 39 35 - -5.39 30 164 39 -8.25
Repayment of Debt		 -0.50 -0.50 -0.50 -0.51 -0.51 14 -0.52 -0.52 -503 -0.53 -0.53
Payment of Dividends		 -69 -69 -69 -69 -70 -71 -71 -71 -72 -75 -76
Other Financing Activities, Net		 -0.01 -0.01 -0.08 - - -0.01 -0.08 - -2.29 0.01 -1.27
Cash Interest Paid		 20 29 20 30 21 34 20 30 23 38 15

Annual Balance Sheets for Sabra Healthcare REIT

This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 2,469 2,266 7,032 6,665 6,069 5,986 5,967 5,748 5,386 5,304 5,493
Cash and Due from Banks		 7.43 26 519 50 39 59 112 49 41 60 72
Restricted Cash		 9.81 9.00 69 9.43 10 6.45 3.89 4.62 5.43 5.87 6.60
Trading Account Securities		 - - 0.00 340 319 289 97 135 137 122 118
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 2,040 2,010 5,994 5,854 5,341 5,285 5,163 4,959 4,617 4,514 4,686
Intangible Assets		 - 26 167 131 102 83 54 40 31 27 65
Other Assets		 300 195 283 281 258 263 537 559 554 574 545
Total Liabilities & Shareholders' Equity		 2,469 2,266 7,032 6,665 6,069 5,986 5,967 5,748 5,386 5,304 5,493
Total Liabilities		 1,415 1,250 3,595 3,411 2,581 2,576 2,587 2,691 2,584 2,562 2,670
Short-Term Debt		 255 26 641 624 - - 0.00 197 94 107 218
Other Short-Term Payables		 35 40 103 95 - 146 143 142 137 118 119
Long-Term Debt		 1,125 1,185 2,753 2,608 2,402 2,372 2,394 2,310 2,320 2,311 2,311
Other Long-Term Liabilities		 - 0.00 98 84 179 58 50 42 33 27 21
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,054 1,016 3,437 3,255 3,488 3,409 3,380 3,056 2,803 2,741 2,824
Total Preferred & Common Equity		 1,054 1,016 3,433 3,250 3,488 3,409 3,380 3,056 2,803 2,741 2,822
Preferred Stock		 0.06 0.06 0.06 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,054 1,016 3,433 3,250 3,488 3,409 3,380 3,056 2,803 2,741 2,822
Common Stock		 1,203 1,210 3,639 3,510 4,074 4,165 4,485 4,489 4,497 4,595 4,839
Accumulated Other Comprehensive Income / (Loss)		 -7.33 -1.80 11 12 -12 -40 -10 19 24 21 -3.57
Other Equity Adjustments		 -142 -192 -217 -272 -573 -716 -1,095 -1,452 -1,718 -1,875 -2,013
Noncontrolling Interest		 0.11 0.04 4.44 4.33 - - - - - 0.00 1.95

Quarterly Balance Sheets for Sabra Healthcare REIT

This table presents Sabra Healthcare REIT's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 5,845 5,556 5,524 5,381 5,374 5,351 5,366 5,233 5,328 5,565 5,591
Cash and Due from Banks		 26 34 27 33 60 36 63 23 95 201 117
Restricted Cash		 4.86 5.15 5.15 5.60 6.00 5.91 5.97 6.24 6.48 6.92 6.92
Trading Account Securities		 208 139 140 136 132 130 131 121 126 118 117
Loans and Leases, Net of Allowance		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Premises and Equipment, Net		 5,019 4,797 4,752 4,603 4,577 4,566 4,574 4,488 4,479 4,630 4,703
Intangible Assets		 48 39 36 33 28 28 29 25 25 60 67
Other Assets		 539 542 564 570 571 585 563 571 596 550 581
Total Liabilities & Shareholders' Equity		 5,845 5,556 5,524 5,381 5,374 5,351 5,366 5,233 5,328 5,565 5,591
Total Liabilities		 2,636 2,580 2,581 2,512 2,607 2,589 2,621 2,531 2,617 2,738 2,803
Short-Term Debt		 139 80 101 33 146 130 153 83 163 282 355
Other Short-Term Payables		 145 143 122 128 113 113 123 112 113 124 118
Long-Term Debt		 2,308 2,317 2,320 2,317 2,317 2,316 2,318 2,311 2,317 2,309 2,310
Other Long-Term Liabilities		 44 40 39 34 31 30 28 25 24 23 20
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 3,209 2,976 2,944 2,869 2,767 2,762 2,745 2,702 2,711 2,827 2,788
Total Preferred & Common Equity		 3,209 2,976 2,944 2,869 2,767 2,762 2,745 2,702 2,711 2,825 2,786
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 3,209 2,976 2,944 2,869 2,767 2,762 2,745 2,702 2,711 2,825 2,786
Common Stock		 4,487 4,490 4,491 4,494 4,498 4,539 4,577 4,594 4,627 4,795 4,835
Accumulated Other Comprehensive Income / (Loss)		 19 17 32 40 31 31 17 15 -2.03 -5.98 0.69
Other Equity Adjustments		 -1,297 -1,531 -1,580 -1,665 -1,762 -1,808 -1,849 -1,907 -1,914 -1,964 -2,050
Noncontrolling Interest		 - - - - - - - - - 2.02 1.88

Annual Metrics And Ratios for Sabra Healthcare REIT

This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 - - - - - - - - - - 249,349,673.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - - 249,349,673.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - - 0.62
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.00 ($0.52) ($0.34) $0.06 $0.54 $0.64
Adjusted Weighted Average Basic Shares Outstanding		 62.24M 65.28M 105.62M 178.31M 187.17M 0.00 219.07M 230.95M 231.20M 233.50M 241.31M
Adjusted Diluted Earnings per Share		 $1.11 $0.92 $1.40 $1.51 $0.37 $0.00 ($0.52) ($0.34) $0.06 $0.54 $0.64
Adjusted Weighted Average Diluted Shares Outstanding		 62.46M 65.52M 105.84M 178.72M 188.13M 0.00 219.07M 230.95M 232.79M 236.05M 244.50M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.37 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 65.19M 65.29M 178.26M 178.32M 205.27M 0.00 230.90M 231.16M 231.48M 237.91M 252.15M
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Quarterly Metrics And Ratios for Sabra Healthcare REIT

This table displays calculated financial ratios and metrics derived from Sabra Healthcare REIT's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - - - - 249,349,673.00 252,145,717.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 249,349,673.00 252,145,717.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.11 0.16
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 18.47% -1.17% 5.71% 10.59% 9.46% 15.26% 12.50% 20.02% 7.19% - 23.52%
EBITDA Growth		 9,518.78% -10.11% 5.97% -12.84% 1.92% 30.02% 16.97% 49.39% -4.43% - 10.74%
EBIT Growth		 165.87% -3.19% 109.37% -24.81% 7.71% 108.72% 48.34% 144.87% -25.38% - -2.65%
NOPAT Growth		 172.29% 76.83% 182.15% -25.06% 55.27% 118.88% 49.30% 147.45% -27.53% - -2.96%
Net Income Growth		 69.84% 120.20% 376.74% 13.15% 297.26% 172.18% 53.52% 173.38% -24.41% - 1.26%
EPS Growth		 68.18% 121.62% 375.00% 11.11% 285.71% 150.00% 54.55% 170.00% -30.77% - -5.88%
Operating Cash Flow Growth		 -23.28% 16.50% -22.69% 13.93% 17.35% 1.56% 52.03% 1.04% 2.37% - 22.55%
Free Cash Flow Firm Growth		 33.76% 64.95% -52.45% -61.76% -91.60% -73.03% 3.18% -59.25% -559.13% - -282.24%
Invested Capital Growth		 -7.73% -6.23% -2.65% -2.89% -0.06% -1.11% -2.57% -0.33% 3.89% - 7.00%
Revenue Q/Q Growth		 2.15% -0.16% 2.67% 5.61% 1.11% 5.13% 0.21% 12.67% -9.70% - -34.59%
EBITDA Q/Q Growth		 2.14% -16.40% 14.13% -7.41% 19.43% 6.66% -0.02% 17.29% -23.60% - 6.88%
EBIT Q/Q Growth		 8.48% -38.61% 50.65% -15.54% 55.41% 18.97% -2.88% 36.38% -52.64% - 12.49%
NOPAT Q/Q Growth		 -22.93% -18.22% 44.12% -17.50% 59.68% 15.28% -1.69% 36.74% -53.24% - 52.58%
Net Income Q/Q Growth		 -171.27% 213.61% 53.03% -8.68% 24.25% 56.76% -13.69% 62.62% -65.64% - 50.34%
EPS Q/Q Growth		 -177.78% 214.29% 37.50% -9.09% 30.00% 53.85% -15.00% 58.82% -66.67% - 45.45%
Operating Cash Flow Q/Q Growth		 18.32% -5.38% -32.95% 51.77% 21.87% -18.11% 0.37% 0.87% 23.47% - 12.51%
Free Cash Flow Firm Q/Q Growth		 -0.78% -20.64% -53.68% 4.85% -78.21% 154.79% 77.21% -58.59% -345.59% - -89.02%
Invested Capital Q/Q Growth		 -2.71% -0.03% 0.27% -0.42% 0.12% -1.08% -1.22% 1.86% 4.37% - 1.88%
Profitability Metrics		 - - - - - - - - - - -
EBITDA Margin		 58.12% 48.67% 52.26% 45.82% 54.12% 54.90% 54.78% 57.03% 48.25% - 49.11%
EBIT Margin		 23.98% 14.75% 19.20% 15.35% 23.60% 26.70% 25.88% 31.33% 16.43% - 20.40%
Profit (Net Income) Margin		 -11.13% 12.66% 18.87% 16.32% 20.05% 29.90% 25.76% 37.17% 14.14% - 21.12%
Tax Burden Percent		 107.86% 93.19% 96.16% 98.53% 101.63% 98.99% 99.52% 100.51% 103.64% - 103.52%
Interest Burden Percent		 -43.02% 92.14% 102.23% 107.87% 83.61% 113.11% 100.00% 118.06% 83.06% - 100.00%
Effective Tax Rate		 0.00% 2.68% 1.66% 1.80% -0.90% 0.81% 1.02% 0.76% 2.01% - 1.33%
Return on Invested Capital (ROIC)		 1.66% 1.37% 1.98% 1.59% 2.60% 2.97% 3.02% 3.81% 1.96% - 3.15%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.08% 1.31% 1.95% 1.66% 2.37% 3.22% 3.03% 4.25% 1.84% - 3.22%
Return on Net Nonoperating Assets (RNNOA)		 0.06% 1.10% 1.65% 1.42% 2.04% 2.80% 2.69% 3.82% 1.67% - 2.97%
Return on Equity (ROE)		 1.72% 2.46% 3.63% 3.01% 4.64% 5.78% 5.70% 7.63% 3.63% - 6.11%
Cash Return on Invested Capital (CROIC)		 8.95% 8.01% 4.67% 4.79% 2.04% 3.52% 5.32% 3.82% -0.57% - -3.92%
Operating Return on Assets (OROA)		 2.30% 1.42% 1.91% 1.57% 2.50% 2.95% 2.97% 3.74% 1.95% - 3.11%
Return on Assets (ROA)		 -1.07% 1.22% 1.88% 1.67% 2.13% 3.30% 2.95% 4.44% 1.68% - 3.22%
Return on Common Equity (ROCE)		 1.72% 2.46% 3.63% 3.01% 4.64% 5.78% 5.70% 7.63% 3.63% - 6.11%
Return on Equity Simple (ROE_SIMPLE)		 -3.08% 0.00% 1.79% 1.89% 3.54% 0.00% 5.21% 6.72% 6.20% - 5.60%
Net Operating Profit after Tax (NOPAT)		 23 19 27 22 35 41 40 55 26 - 39
NOPAT Margin		 16.79% 13.75% 19.30% 15.08% 23.81% 26.11% 25.62% 31.09% 16.10% - 20.13%
Net Nonoperating Expense Percent (NNEP)		 1.58% 0.06% 0.02% -0.08% 0.23% -0.25% -0.01% -0.44% 0.12% - -0.08%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Operating Expenses to Revenue		 75.78% 85.52% 80.90% 84.76% 76.50% 73.38% 74.23% 68.80% 83.72% - 79.71%
Earnings before Interest and Taxes (EBIT)		 33 20 27 23 35 42 40 55 26 - 39
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 79 66 73 67 80 86 86 101 77 - 95
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.03 1.07 1.19 1.27 1.59 1.47 1.54 1.62 1.58 - 1.74
Price to Tangible Book Value (P/TBV)		 1.05 1.08 1.20 1.28 1.61 1.48 1.55 1.63 1.62 - 1.78
Price to Revenue (P/Rev)		 5.52 5.60 6.04 6.28 7.65 6.81 6.84 6.88 6.90 - 5.88
Price to Earnings (P/E)		 0.00 217.85 66.31 66.92 44.86 31.76 29.53 24.06 25.53 - 31.05
Dividend Yield		 9.35% 9.26% 8.45% 7.94% 6.45% 7.06% 6.87% 6.51% 6.44% - 6.24%
Earnings Yield		 0.00% 0.46% 1.51% 1.49% 2.23% 3.15% 3.39% 4.16% 3.92% - 3.22%
Enterprise Value to Invested Capital (EV/IC)		 1.01 1.03 1.09 1.13 1.30 1.24 1.28 1.30 1.27 - 1.36
Enterprise Value to Revenue (EV/Rev)		 9.83 10.02 10.46 10.59 11.86 10.79 10.72 10.61 10.58 - 8.97
Enterprise Value to EBITDA (EV/EBITDA)		 26.39 18.46 19.46 20.94 23.85 20.83 20.47 19.23 19.69 - 20.47
Enterprise Value to EBIT (EV/EBIT)		 0.00 56.30 53.42 59.70 66.68 50.59 46.84 39.36 42.06 - 47.43
Enterprise Value to NOPAT (EV/NOPAT)		 107.67 63.07 53.84 60.11 65.71 50.99 46.47 37.35 39.65 - 49.15
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.24 17.85 19.92 20.02 21.86 20.53 19.29 19.97 20.09 - 20.16
Enterprise Value to Free Cash Flow (EV/FCFF)		 10.85 12.43 22.92 23.30 63.68 34.89 23.73 34.07 0.00 - 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.82 0.86 0.89 0.89 0.90 0.88 0.89 0.91 0.92 - 0.96
Long-Term Debt to Equity		 0.81 0.83 0.84 0.84 0.84 0.84 0.86 0.85 0.82 - 0.83
Financial Leverage		 0.79 0.84 0.85 0.85 0.86 0.87 0.89 0.90 0.91 - 0.92
Leverage Ratio		 1.85 1.90 1.90 1.91 1.91 1.93 1.94 1.95 1.96 - 1.97
Compound Leverage Factor		 -0.79 1.75 1.95 2.06 1.60 2.18 1.94 2.30 1.63 - 1.97
Debt to Total Capital		 45.02% 46.28% 47.10% 46.97% 47.37% 46.86% 46.97% 47.77% 47.82% - 48.87%
Short-Term Debt to Total Capital		 0.63% 1.81% 2.79% 2.50% 2.93% 2.07% 1.62% 3.14% 5.21% - 6.51%
Long-Term Debt to Total Capital		 44.40% 44.47% 44.30% 44.47% 44.44% 44.80% 45.35% 44.63% 42.62% - 42.36%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% - 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% - 0.03%
Common Equity to Total Capital		 54.98% 53.72% 52.90% 53.03% 52.63% 53.14% 53.03% 52.23% 52.14% - 51.09%
Debt to EBITDA		 11.75 8.31 8.44 8.68 8.72 7.90 7.51 7.05 7.44 - 7.38
Net Debt to EBITDA		 11.55 8.15 8.22 8.53 8.47 7.68 7.42 6.76 6.85 - 7.04
Long-Term Debt to EBITDA		 11.58 7.98 7.94 8.22 8.18 7.55 7.26 6.59 6.63 - 6.40
Debt to NOPAT		 47.92 28.38 23.35 24.91 24.01 19.34 17.06 13.69 14.99 - 17.72
Net Debt to NOPAT		 47.13 27.83 22.73 24.48 23.34 18.81 16.85 13.13 13.79 - 16.90
Long-Term Debt to NOPAT		 47.26 27.27 21.97 23.58 22.53 18.48 16.47 12.79 13.36 - 15.36
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.04% - 0.03%
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 460 365 169 177 39 98 175 72 -177 - -318
Operating Cash Flow to CapEx		 322.56% 373.85% 408.16% 644.89% 706.12% 515.16% 1,031.26% 1,399.22% 941.81% - 829.99%
Free Cash Flow to Firm to Interest Expense		 16.34 13.07 5.95 6.05 1.31 3.51 6.44 2.62 -6.14 - -11.19
Operating Cash Flow to Interest Expense		 2.96 2.82 1.86 2.73 3.31 2.85 2.96 2.94 3.46 - 3.46
Operating Cash Flow Less CapEx to Interest Expense		 2.04 2.06 1.40 2.31 2.84 2.29 2.67 2.73 3.09 - 3.05
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.12 - 0.15
Fixed Asset Turnover		 0.11 0.11 0.12 0.12 0.12 0.13 0.13 0.14 0.14 - 0.18
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5,218 5,217 5,231 5,209 5,215 5,159 5,096 5,191 5,418 - 5,453
Invested Capital Turnover		 0.10 0.10 0.10 0.11 0.11 0.11 0.12 0.12 0.12 - 0.16
Increase / (Decrease) in Invested Capital		 -437 -347 -142 -155 -3.28 -58 -134 -17 203 - 357
Enterprise Value (EV)		 5,279 5,364 5,680 5,903 6,761 6,375 6,521 6,766 6,855 - 7,392
Market Capitalization		 2,968 2,997 3,282 3,499 4,360 4,024 4,156 4,388 4,470 - 4,849
Book Value per Share		 $12.41 $12.12 $11.96 $11.93 $11.72 $11.59 $11.36 $11.40 $11.78 - $11.05
Tangible Book Value per Share		 $12.27 $11.99 $11.83 $11.81 $11.59 $11.47 $11.25 $11.29 $11.53 - $10.78
Total Capital		 5,218 5,217 5,231 5,209 5,215 5,159 5,096 5,191 5,418 - 5,453
Total Debt		 2,349 2,414 2,463 2,447 2,470 2,418 2,394 2,480 2,591 - 2,665
Total Long-Term Debt		 2,317 2,320 2,317 2,316 2,318 2,311 2,311 2,317 2,309 - 2,310
Net Debt		 2,311 2,367 2,397 2,404 2,401 2,351 2,365 2,378 2,384 - 2,542
Capital Expenditures (CapEx)		 26 21 13 12 14 16 7.78 5.79 11 - 12
Net Nonoperating Expense (NNE)		 38 1.47 0.60 -1.82 5.58 -5.92 -0.22 -11 3.12 - -1.91
Net Nonoperating Obligations (NNO)		 2,349 2,414 2,463 2,447 2,470 2,418 2,394 2,480 2,591 - 2,665
Total Depreciation and Amortization (D&A)		 46 46 46 45 45 44 45 45 51 - 55
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.28 $0.09 $0.10 $0.16
Adjusted Weighted Average Basic Shares Outstanding		 231.22M 231.20M 231.45M 231.62M 234.29M 233.50M 237.89M 237.98M 239.90M 241.31M 252.14M
Adjusted Diluted Earnings per Share		 ($0.07) $0.08 $0.11 $0.10 $0.13 $0.20 $0.17 $0.27 $0.09 $0.11 $0.16
Adjusted Weighted Average Diluted Shares Outstanding		 231.22M 232.79M 233.37M 233.75M 237.04M 236.05M 240.30M 240.93M 243.56M 244.50M 255.97M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 231.22M 231.48M 231.50M 234.26M 236.59M 237.91M 237.94M 239.79M 249.35M 252.15M 252.19M
Normalized Net Operating Profit after Tax (NOPAT)		 57 73 84 91 65 100 99 120 96 - 124
Normalized NOPAT Margin		 41.97% 54.20% 60.11% 61.93% 44.09% 63.74% 63.53% 67.79% 60.55% - 64.07%
Pre Tax Income Margin		 -10.32% 13.59% 19.63% 16.56% 19.73% 30.21% 25.88% 36.98% 13.65% - 20.40%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 1.16 0.72 0.94 0.77 1.19 1.49 1.49 2.01 0.91 - 1.39
NOPAT to Interest Expense		 0.81 0.67 0.95 0.76 1.20 1.45 1.48 1.99 0.89 - 1.37
EBIT Less CapEx to Interest Expense		 0.24 -0.04 0.48 0.35 0.72 0.93 1.21 1.79 0.54 - 0.97
NOPAT Less CapEx to Interest Expense		 -0.11 -0.09 0.49 0.33 0.73 0.90 1.19 1.78 0.52 - 0.95
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 -313.96% 2,016.92% 560.72% 531.00% 286.65% 221.09% 200.39% 155.77% 163.18% - 188.30%
Augmented Payout Ratio		 -313.96% 2,016.92% 560.72% 531.00% 286.65% 153.13% 200.39% 155.77% 163.18% - 188.30%

Financials Breakdown Chart

Key Financial Trends

Here are concise, investor-focused takeaways on Sabra Health Care REIT (SBRA) using the quarterly statements provided for the last four years. The items are organized to highlight positive trends first, then neutral observations, and finally potential negatives.

  • Strong Q4 2025 revenue spike driven by non-interest sources. Total Revenue reached $295.5M in Q4 2025, up from Q3 2025’s $159.2M. Non-interest income was the primary driver (Service Charges on Deposit Accounts: $108.4M; Other Non-Interest Income: $92.9M), with Total Non-Interest Income at $211.96M.
  • Solid quarterly earnings in Q4 2025. Consolidated Net Income to Common Shareholders came in at about $27.23M in Q4 2025, up from the prior quarter’s levels, reflecting improved profitability even after notable charges.
  • Healthy operating cash flow supports liquidity. Net Cash From Continuing Operating Activities was $87.43M in Q4 2025, continuing the positive operating cash flow trend observed in 2025.
  • Stable quarterly dividends. Cash Dividends to Common per Share remained at $0.30 in 2025 across Q1–Q4, signaling dividend policy stability (annualized ≈$1.20 per share).
  • Solid balance sheet positioning for a REIT. Total assets around $5.56B (Q3 2025), with Total Liabilities near $2.74B and Total Equity around $2.83B, providing a healthy asset base and equity cushion to absorb shocks.
  • Diversified revenue mix appears positive for stability. Non-interest income has shown growth and diversification alongside net interest income, suggesting less reliance on interest income alone over the period.
  • Debt levels are substantial but manageable within the asset base. Long-term debt sits in the low-to-mid $2B range, with total liabilities near $2.74B, which is typical for a healthcare REIT with a sizable property portfolio.
  • Occasional one-off charges noted in 2025. Q4 2025 includes notable one-off costs (Other Special Charges: $192.9M; Total Non-Interest Expense: $260.9M), which weigh near-term earnings but may not reflect ongoing ongoing operations.
  • Material one-time charges weigh 2025 earnings. The Q4 2025 period included sizable one-off items (Other Special Charges of $192.9M and impairment activity), reducing quarterly earnings visibility.
  • Cash flow is pressured by financing outflows. Net Change in Cash & Equivalents for Q4 2025 was a negative $130.0M, and Net Cash From Financing Activities was also heavily cash-outflowed, indicating ongoing cash usage beyond operating activities.
  • Some year-over-year comparisons are complicated by restatements. Various quarters across 2022–2024 include restated results (e.g., restatements in 2023–2024 periods), which can complicate direct trend comparisons without restatement context.
05/05/26 06:33 PM ETAI Generated. May Contain Errors.

Frequently Asked Questions About Sabra Healthcare REIT's Financials

When does Sabra Healthcare REIT's fiscal year end?

According to the most recent income statement we have on file, Sabra Healthcare REIT's financial year ends in December. Their financial year 2025 ended on December 31, 2025.

How has Sabra Healthcare REIT's net income changed over the last 10 years?

Sabra Healthcare REIT's net income appears to be on a downward trend, with a most recent value of $155.51 million in 2025, rising from $79.38 million in 2015. The previous period was $126.71 million in 2024. View Sabra Healthcare REIT's forecast to see where analysts expect Sabra Healthcare REIT to go next.

How has Sabra Healthcare REIT's revenue changed over the last 10 years?

Over the last 10 years, Sabra Healthcare REIT's total revenue changed from $240.96 million in 2015 to $787.51 million in 2025, a change of 226.8%.

How much debt does Sabra Healthcare REIT have?

Sabra Healthcare REIT's total liabilities were at $2.67 billion at the end of 2025, a 4.2% increase from 2024, and a 88.7% increase since 2015.

How much cash does Sabra Healthcare REIT have?

In the past 10 years, Sabra Healthcare REIT's cash and equivalents has ranged from $7.43 million in 2015 to $518.63 million in 2017, and is currently $71.54 million as of their latest financial filing in 2025.


Related Companies

Financial statements for NASDAQ:SBRA last updated on 5/3/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Your book attached
Your Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...
Profits Run | Sponsoredtc pixel
My feud with Zohran Mamdani
Emmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...
Stansberry Research | Sponsoredtc pixel
Sell 99% of Your Stocks, Do THIS Instead…
Millionaire Trader Exposes: "The Single Stock Income Plan" With over 6,000 stocks on the market to choose ...
The Oxford Club | Sponsoredtc pixel
Trade this between 9:30 and 10:45 am EST
The first 75 minutes of the trading day may be the most overlooked window for consistent opportunities.If you ...
Base Camp Trading | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
Elon Unveils AI Passive Income Stream for Millions of Americans
During Tesla's last earnings call, Elon Musk outlined a new AI-driven approach he says could generate $30,000-...
InvestorPlace | Sponsoredtc pixel
Invest in SpaceX Before IPO
SpaceX is already one of the most valuable private companies on Earth, and some analysts believe its valuation...
NXT Wave Research | Sponsoredtc pixel
URGENT: $2 Gold Stock With Major Discovery
A $2 gold stock is said to quietly control what may be the largest gold deposit in the world - worth nearly $1...
Paradigm Press | Sponsoredtc pixel